Total Valuation
CytoDyn has a market cap or net worth of $382.07M. The enterprise value is $10.00T>.
Market Cap$382.07M
Enterprise Value$10.00T>
Share Statistics
CytoDyn has 1,469,518,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,469,518,100
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
CytoDyn’s return on equity (ROE) is 0.39 and return on invested capital (ROIC) is 78.65%.
Return on Equity (ROE)0.39
Return on Assets (ROA)-3.06
Return on Invested Capital (ROIC)78.65%
Return on Capital Employed (ROCE)0.55
Revenue Per Employee0.00
Profits Per Employee-3.05M
Employee Count14
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of CytoDyn is ―. CytoDyn’s PEG ratio is 0.00455.
PE Ratio―
PS Ratio0.00
PB Ratio-3.50
Price to FCF-22.24
Price to Operating Cash Flow-15.95
PEG Ratio0.00455
Income Statement
In the last 12 months, CytoDyn had revenue of 0.00 and earned -42.70M in profits. Earnings per share was -0.03.
Revenue0.00
Gross Profit-17.00K
Operating Income-21.81M
Pretax Income-42.70M
Net Income-42.70M
EBITDA-21.79M
Earnings Per Share (EPS)-0.03
Cash Flow
In the last 12 months, operating cash flow was -22.53M and capital expenditures 0.00, giving a free cash flow of -22.53M billion.
Operating Cash Flow-22.53M
Free Cash Flow-22.53M
Free Cash Flow per Share-0.02
Dividends & Yields
CytoDyn pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.72
52-Week Price Change2.36%
50-Day Moving Average0.21
200-Day Moving Average0.25
Relative Strength Index (RSI)73.08
Average Volume (3m)2.01M
Important Dates
CytoDyn upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
CytoDyn as a current ratio of 0.26, with Debt / Equity ratio of -36.51%
Current Ratio0.26
Quick Ratio0.26
Debt to Market Cap0.10
Net Debt to EBITDA-1.22
Interest Coverage Ratio-8.69
Taxes
In the past 12 months, CytoDyn has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
CytoDyn EV to EBITDA ratio is -18.82, with an EV/FCF ratio of -23.78.
EV to Sales0.00
EV to EBITDA-18.82
EV to Free Cash Flow-23.78
EV to Operating Cash Flow-23.78
Balance Sheet
CytoDyn has $16.36M in cash and marketable securities with $35.81M in debt, giving a net cash position of -$19.45M billion.
Cash & Marketable Securities$16.36M
Total Debt$35.81M
Net Cash-$19.45M
Net Cash Per Share-$0.01
Tangible Book Value Per Share-$0.09
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for CytoDyn is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast-143.41%